ClinicalTrials.gg
RecruitingNCT05654922Updated Aug 5, 2026

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

A Phase 3 interventional study of ARINA-1 and Standard of care only in Pre-Bronchiolitis Obliterans Syndrome, sponsored by Renovion, Inc.. Recruiting at 22 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Renovion, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 70 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.

Planned enrollment
77th of 260
100 · median 45
Started
2023
with 12 others
Phase 3
30 of 300
4 open now
Primary completion
2028-02
later than 42 of 68 live
Registered
239th of 300
by date

Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 77th largest by planned enrollment of the 260 interventional ones that give a count, is one of 13 that started in 2023, is one of 30 in phase 3, reaches primary completion later than 42 of the 68 other live ones, and was the 239th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this Phase 3 clinical trial is to compare ARINA-1 (a nebulized immunomodulatory agent) plus Standard of Care vs Standard of Care alone. The main question it aims to answer are:

  • Evaluate the effectiveness of ARINA-1 in preventing bronchiolitis obliterans syndrome (BOS) progression in participants with a bilateral lung transplant
  • To evaluate the effectiveness of ARINA-1 on improving quality of life decline and preventing or delaying the use of augmented immunosuppression in participants with pre-BOS relative to SOC.

Participants will have clinic visits at screening, randomization (day 1) and weeks 4, 12, 18, and 24. After week 24, participants will have clinic visits at weeks 32, 40, and 48.

Participants will also have a telehealth visit on day 2 and phone calls to assess adverse events (AEs), serious adverse events (SAEs), and review patient education will occur during weeks 5, 8, 36, and 44.

03

Conditions studied

  • Pre-Bronchiolitis Obliterans Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Bilateral lung transplant >12 months from the time of Visit 1 / Randomization
  2. Age 18-75 years old at the time of consent
  3. Routinely followed at enrolling site
  4. Willing and able to comply with visit schedule and at-home requirements
  5. 10-24% decrease in from the post-transplant baseline within the last 12 months.
  6. Capable of giving
  7. On a stable maintenance regimen of azithromycin for >4 weeks prior to the Screening Visit
  8. On a stable 2-agent or 3-agent regimen that includes a , a calcineurin inhibitor (CNI), and, optionally, a cell cycle inhibitor (e.g., mycophenolate, azathioprine) >4 weeks prior to Screening
  9. If a woman of (WOCBP), must agree to use a reliable method of for the entire duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Positive urine pregnancy test at screening and baseline visit
  2. Diagnosis of active congestive heart failure or symptomatic coronary artery disease > grade 3 based on the Functional Classification (NYHA) criteria
  3. Restrictive allograft syndrome (RAS) defined by radiographic interstitial or alveolar opacities on chest X-ray or CT scan that are consistent with RAS
  4. Have advanced BOS, defined by >24% decrease in in post-transplant baseline
  5. A diagnosis of probable antibody-mediated rejection (AMR) \<12 months prior to the baseline visit
  6. Donor-specific antibodies (DSA) identified \<6 months prior to the baseline visit. *The presence of DSA >6 months from the baseline visit is acceptable for enrollment into the study.
  7. Unresolved diffuse alveolar damage
  8. Receiving mechanical ventilation
  9. Chronic kidney disease stage IV or higher, including on dialysis
  10. Initiating a new maintenance therapy or changing maintenance therapy (e.g., changing tacrolimus to cyclosporine) \<30 days prior to the baseline visit.
  11. Have initiated or changed mTOR maintenance therapy \<3 months prior to Clinic Visit 1 (mTOR use for >3 months is allowed)
  12. Initiating or changing antibiotic (including azithromycin), antiviral, or antifungal therapy \<14 days prior to the baseline visit.
  13. Use of alemtuzumab \<6 months prior to the baseline visit
  14. Use of anti-thymocyte therapies (e.g., anti-thymocyte globulin) or photopheresis \<90 days prior to the Screening Visit. Prior use of Trikafta (elexacaftor, ivacaftor, and tezacaftor is allowed as long as the participant has been on stable dose for >90 days prior to the Screening Visit.
  15. Initiating a multivitamin or other supplement (inhaled, oral, or IV) containing vitamin C, glutathione, or N-acetylcysteine \<90 days prior to the baseline visit
  16. Significant unstable comorbidities, in the opinion of the site investigator
  17. Allery or previous adverse reaction to azithromycin
  18. A diagnosis of dynamic collapse / tracheobrochomalacia \<90 days of the baseline visit.
  19. Subjects currently participating in, or who have participated in an interventional (drug or device) clinical study \<30 days of the baseline visit.
  20. Have been diagnosed with ARAD within 6 weeks of the Screening Visit.
  21. Have used belatacept \<6 months prior to Clinic Visit 1
  22. Have had an initial treatment of bronchial stents or cryotherapy within 12 months of the Screening Visit, or had bronchial stents removed within the last 3 months of the Screening Visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    ARINA-1 plus standard of care

    ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH); fixed dose, 4 mL solution inhaled twice daily via nebulization plus standard 3-therapy immunosuppression regimen and azithromycin

    Drug: ARINA-1

  • Other
    Standard of care only

    Standard 3-therapy immunosuppression regimen and azithromycin

    Other: Standard of care only

Interventions

  • DrugARINA-1

    ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)

  • OtherStandard of care only

    Standard 3-therapy immunosuppression regimen and azithromycin

06

What researchers measure

Primary outcomes

  1. Percentage change from baseline in FEV1 (%ΔFEV1)

    Week 24 (mL) - Baseline (mL) = ΔFEV1 (mL) ΔFEV1 (mL) / Baseline (mL) x 100 = %ΔFEV1

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage change from baseline of Forced Expiratory Volume in one second (FEV1)

    Week 48 (mL) - Baseline (mL) = ΔFEV1 (mL) ΔFEV1 (mL) / Baseline (mL) x 100 = %ΔFEV1

    Time frame: 48 weeks

  2. Percentage change from baseline of Forced Vital Capacity (FVC)

    Time frame: 24 weeks

  3. Percentage change from baseline of FVC

    Time frame: 48 weeks

  4. Percentage change from baseline of FEF25-75%

    Time frame: 24 weeks

  5. Percentage change from baseline of FEF25-75%

    Time frame: 48 weeks

  6. Number of participants in each arm with augmented immunosuppression

    number

    Time frame: 24 weeks

  7. Number of participants in each arm with augmented immunosuppression

    Time frame: 48 weeks

  8. Time to initiation of augmented immunosuppression

    Length of time to when participant requires a change in their immunosuppression regimen

    Time frame: over the duration of the 48 week trial

  9. Change from baseline in Saint George's Respiratory Questionnaire total score

    quality of life questionnaire, total score of 0 to 100, higher score = more limitations

    Time frame: 24 weeks

  10. Change from baseline in Saint George's Respiratory Questionnaire total score

    quality of life questionnaire, total score of 0 to 100, higher score = more limitations

    Time frame: 48 weeks

  11. Proportion of participants requiring the use of antimicrobial agents to treat a pulmonary infection

    Time frame: 48 weeks

07

Study locations

18 of 22 sites recruiting
  • Dignity Health - St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of California Los Angeles School of Medicine
    Los Angeles, California 90095, United States
    Recruiting
    • Sam Weigt, MD · Principal investigator
  • University of California San Diego Health
    San Diego, California 92103, United States
    Recruiting
    • Kamyar Afshar, MD · Principal investigator
  • Advent Health
    Orlando, Florida 32803, United States
    Recruiting
    • Suresh Manickavel, MD · Principal investigator
  • University of South Florida
    Tampa, Florida 33606, United States
    Recruiting
    • Satish Chandrashekaran, MD · Principal investigator
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
    Recruiting
    • Daniel Dilling, MD · Principal investigator
  • University of Iowa Hospital
    Iowa City, Iowa 52242, United States
    Recruiting
    • Julia Klesney-Tait, MD, PhD · Principal investigator
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Recruiting
    • Christian Merlo, MD · Principal investigator
  • University of Minnesota Medical School
    Minneapolis, Minnesota 55455, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Not yet recruiting
    • Yuka Yuka Furuya, MD · Principal investigator
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Chad Witt, MD · Principal investigator
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
    Recruiting
    • Selim Arcasoy, MD · Principal investigator
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Marie Budev, DO · Principal investigator
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43221, United States
    Recruiting
    • Justin Rosenheck, DO · Principal investigator
  • Temple University Hospital
    Philadelphia, Pennsylvania 19122, United States
    Recruiting
    • Rachel Criner, MD · Principal investigator
  • Medical University of South Carolina
    Charleston, South Carolina 29452, United States
    Recruiting
    • Tim Whelan, MD · Principal investigator
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Not yet recruiting
    • Ciara Shaver, MD, PhD · Principal investigator
  • University of Texas Southwestern Medical Center
    Dallas, Texas 45390, United States
    Recruiting
    • Vaidehi Kaza, MD · Principal investigator
  • Baylor Scott and White Research Institute
    Dallas, Texas 75246, United States
    Recruiting
    • Samir Kumar, MD · Principal investigator
  • Baylor St. Luke's Medical Center
    Houston, Texas 77030, United States
    Recruiting
    • Prangthip Charoenpong, MD, MPH · Principal investigator
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Recruiting
    • Howard Huang, MD · Principal investigator
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
    Recruiting
    • Shambhu Aryal, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Feb 2028, 58 months after the start.

Of 30 phase 3 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 58 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Dec 16, 2022
StartActual
Apr 10, 2023
Primary completionEst.
Feb 2028
CompletionEst.
Aug 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05654922
Lead sponsor
Renovion, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Apr 10, 2023
Primary completion
Feb 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Carolyn Durham, PhD
Contact
info@renovion.com
919-240-7034
Will Anderson
Contact
info@renovion.com
919-240-7034
Tim Whelan, MD
principal investigator · Medical University of South Carolina

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion